Recent advances in preclinical models for lung squamous cell carcinoma

Area of Science:

• Oncology
• Cancer Biology
• Translational Medicine

Background:

• Lung squamous cell carcinoma (LUSC) is a significant non-small cell lung cancer subtype with limited targeted therapy options.
• While immunotherapy has advanced LUSC treatment, a deeper understanding of LUSC biology is needed.
• Effective preclinical models are essential for studying cancer development and evaluating novel therapeutic strategies.

Purpose of the Study:

• To review recent advancements in LUSC preclinical models.
• To highlight the importance of models that preserve the tumor immune microenvironment.
• To discuss the role of these models in precision medicine and immunotherapy for LUSC.

Main Methods:

• Focus on genetically engineered mouse models (GEMMs) for LUSC.
• Discussion of organoid models for LUSC research.
• Integration of preclinical models within the context of precision medicine and immunotherapy.

Main Results:

• GEMMs and organoids are increasingly sophisticated tools for LUSC research.
• These models facilitate the study of LUSC under conditions that mimic the human tumor immune microenvironment.
• Advances in modeling are critical for identifying new therapeutic targets and strategies.

Conclusions:

• Improved preclinical models are vital for advancing LUSC research and treatment.
• Genetically engineered mouse models and organoids are key to understanding LUSC biology and response to therapy.
• These models are instrumental in the development of precision medicine and immunotherapy for LUSC.